Skip to main content
Skip to section navigation
Skip to footer
Home
Home
About Us
Programs
Anti-TNF
Synthetic CBD Analogs (SCAs)
a7nAChR Program
Pipeline
Leadership
Investors
Contact Us
Contact Us
All SEC Filings
Investors
Investors
Overview
News & Events
Overview
Press Releases
IR Calendar
Email Alerts
Company Info
Overview
Management Team
Presentations
Contacts
FAQ
Financial Info
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Filing Type:
View All
10-K
10-K/A
10-Q
10-Q/A
25-NSE
3
3/A
4
4/A
424B3
424B4
424B5
425
8-A12B
8-K
8-K/A
ARS
AW
CERTNAS
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
NT 10-K
NT 10-Q
POS AM
PRE 14A
S-1
S-1/A
S-3
S-4
S-4/A
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
UPLOAD
Year:
View All
2024
2023
2022
2021
2020
2019
2018
2017
2016
Date
Form
Description
PDF
XBRL
Pages
03/07/17
DRS/A
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
161
02/03/17
UPLOAD
SEC-generated letter
4
01/19/17
DRSLTR
Correspondence Related to Draft Registration Statement
11
01/19/17
DRS/A
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
162
12/14/16
UPLOAD
SEC-generated letter
7
11/16/16
DRS
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
Documents
expand_more
EX-3.1
EX-3.3
EX-10.1
EX-10.5
EX-10.6
196
rss_feed
Filing RSS
Previous Page
arrow_back
Page
1
…
…
Page
43
Page
44
Page
45
Page
46
Page
47
Page
48
Page
49
Page
50
Page
51
Page
52
Email Alerts
Contacts
RSS News Feed